Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Cash from Operations: 2018-2024

Historic Cash from Operations for Silence Therapeutics (SLN) over the last 7 years, with Dec 2024 value amounting to -$67.6 million.

  • Silence Therapeutics' Cash from Operations rose 57.43% to -$10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$57.3 million, marking a year-over-year decrease of 23.95%. This contributed to the annual value of -$67.6 million for FY2024, which is 36.75% down from last year.
  • According to the latest figures from FY2024, Silence Therapeutics' Cash from Operations is -$67.6 million, which was down 36.75% from -$49.5 million recorded in FY2023.
  • In the past 5 years, Silence Therapeutics' Cash from Operations registered a high of $9.4 million during FY2021, and its lowest value of -$67.6 million during FY2024.
  • Moreover, its 3-year median value for Cash from Operations was -$57.0 million (2022), whereas its average is -$58.0 million.
  • As far as peak fluctuations go, Silence Therapeutics' Cash from Operations tumbled by 903.30% in 2020, and later skyrocketed by 152.86% in 2021.
  • Silence Therapeutics' Cash from Operations (MRY) stood at -$17.7 million in 2020, then skyrocketed by 152.86% to $9.4 million in 2021, then crashed by 709.17% to -$57.0 million in 2022, then rose by 13.29% to -$49.5 million in 2023, then crashed by 36.75% to -$67.6 million in 2024.
  • Its last three reported values are -$67.6 million in FY2024, -$49.5 million for FY2023, and -$57.0 million during FY2022.